Impact of switching to bictegravir- or dolutegravir-based antiretroviral therapy on weight in people living with HIV during the COVID-19 pandemic
Switching to BIC- or DTG-based regimens during the COVID-19 pandemic was not associated with weight gain in treatment-experienced, virologically-suppressed PLWH in this single-center study. The study findings may reassure clinicians who are hesitant about switching treatment-experienced patients to newer BIC- or DTG-containing regimens due to concerns about potential weight gain.
Authors
- Monica Douglas
- Nardine Karam (ORCID: https://orcid.org/0009-0004-8602-494X)
- Stanley Moy
Institutions
- State University of New York (US)
- Long Island University (US)
- SUNY Downstate Health Sciences University (US)
- Staten Island University Hospital (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1080/03007995.2025.2514761
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00